| Phamacology standards |
 |
The company has synthesized 6-MNA (GL-1189, CAS 23981-47-7) a broad-spectrum COX inhibitor. 6-MNA is available in gram quantities for pharmacological research studies at the very high level of purity of 98%. |
| Retrohydroxamates |
 |
A new cluster of ethyl retrohydroxamates featuring phenyl (GL-1190), and furyl substituted compounds (GL-1191). |
| Pyridines |
 |
Several unique 4-carboxy-pyridines with 6-ethyl substitutions have been developed (GL-1192, GL-1193 and GL-1194). |
| Pyrazine derivates |
 |
As part of our project to develop novel pyrazine building blocks, the company proudly announces 3 new building blocks: an aliphatic disubstituted compound (GL-1195) and 2 poly-brominated (GL-1196 and GL-1197) scaffolds for kinase target exploration. Additionally, 3 new polybrominated imidazo-pyrazine have been synthesized (GL-1198, GL-1199 and GL-1200) |
| Terpenoid analogs |
 |
Carvone oxime ether (GL-1201) is an additional member of the terpenoid family, which has been proven to be suitable for screening steroid type receptors. |
| Pyrimidinopyrazole aldehydes |
 |
InFarmatik has extended our in-house kinase program by issuing four new imidazopyrimidine derivatives (GL-1202 - GL-1205) |
| Fused imidasoles |
 |
Our largest and most diverse set of compounds is the fused imdazole family. This set has been extended by the addition of five novel unique substances (GL-1206 - GL-1210). |
| Miscellaneous |
 |
A unique p-amino-cinnamoyl ester offers a variety of transformation opportunities (GL-1211) |
| Diamines |
 |
3 novel mono-Boc- protected derivatives are available for orthogonal synthesis (GL-1212, GL-1213 and GL-1214). GL-1215 and GL-1216 are related scaffolds for heterocyclic and orthogonal medchem focused library synthesis. |
| Amino nitriles |
 |
We have synthesized two Amino nitriles: (GL-1218, GL-1219) |
| Miscellaneous |
 |
Intermediates for 3-substituted five member ring heterocycles are always a good starting point for building novel compound libraries. GL-1220 and GL-1221 are reactive intermediates offering high potential for building chemistry around them. |
| Quinoxalines |
 |
Lipinsky’s Rule of 5 is often disregarded when designing novel compounds. GL-1222, GL-1223 and GL-1224 are structures that are useful in extending the diversity of your compound library, while still maintaining very favorable drug-like and safety profiles. |